Clinical trial · Interventional
Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer
Phase II Study of Weekly Paclitaxel and Gemcitabine in Platinum-Resistant Ovarian Cancer
NCT00003449CI-TRIAL-00014635completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus paclitaxel and gemcitabine in treating patients with platinum-resistant recurrent ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dexamethasone | Drug | Dexamethasone | ALIAS |
| gemcitabine hydrochloride | Drug | Gemcitabine | ALIAS |
| paclitaxel | Drug | Paclitaxel | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed recurrent ovarian epithelial cancer * Platinum resistant disease defined as: * Progression during the most recent platinum-based chemotherapy OR * Relapse less than 6 months after platinum-based chemotherapy * Measurable or evaluable disease * Elevated CA-125 only allowed * Positive cytology only not eligible PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * SWOG 0-2 Hematopoietic: * Granulocyte count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin less than 2 times upper limit of normal (ULN) * AST less than 3 times ULN Renal: * Creatinine no greater than 2 mg/dL Neurologic: * No peripheral neuropathy greater than grade 2 Other: * No other serious medical illness or psychiatric conditions. PRIOR CONCURRENT THERAPY: Biologic therapy: * No concurrent hematopoietic growth factors Chemotherapy: * See Disease Characteristics * No prior gemcitabine * No prior paclitaxel administered weekly Endocrine therapy: * Not specified Radiotherapy: * Not specified Surgery: * Not specified Other: * Recovered from acute toxic effects secondary to prior therapy
References
Publications (0)
Data not yet available
No reference posted for this study.